Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma

Ester Simeone, Antonio Maria Grimaldi, Lucia Festino, Diana Giannarelli, Vito Vanella, Marco Palla, Marcello Curvietto, Assunta Esposito, Giuseppe Palmieri, Nicola Mozzillo, Paolo Antonio Ascierto

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The optimal sequencing of targeted treatment and immunotherapy in the treatment of advanced melanoma is a key question and prospective studies to address this are ongoing. Previous observations suggest that treating first with targeted therapy may select for more aggressive disease, meaning that patients may not gain full benefit from subsequent immunotherapy. In a single-center retrospective analysis, we investigated whether response to pembrolizumab was affected by previous BRAF inhibitor therapy. A total of 42 patients with metastatic cutaneous or mucosal melanoma who had received previous treatment with ipilimumab were treated with pembrolizumab as part of the Italian expanded access program. Sixteen of these patients had BRAF-mutated melanoma and had also been previously treated with a BRAF inhibitor (vemurafenib or dabrafenib), while 26 had BRAF wild-type melanoma (no previous BRAF inhibitor). Patients with BRAF-mutant melanoma who were previously treated with BRAF inhibitors had a significantly lower median progression-free survival (3 [2.3–3.7] versus not reached [2–8+] mo; p = 0.001) and disease control rate (18.6% versus 65.4%; p = 0.005) than patients with BRAF wild-type, while there was also a trend toward a lower response rate (assessed using immune-related response criteria) although this was not significantly different between groups (12.5% versus 36.4%; p = 0.16). These data are consistent with previous reports that BRAF inhibitor therapy may affect subsequent response to immunotherapy.

Original languageEnglish
Article numbere1283462
JournalOncoImmunology
Volume6
Issue number3
DOIs
Publication statusPublished - Mar 4 2017

Fingerprint

Melanoma
Immunotherapy
Therapeutics
Disease-Free Survival
pembrolizumab
Prospective Studies
Skin

Keywords

  • Anti-PD-1 antibodies
  • BRAF inhibitors
  • immunotherapy
  • melanoma
  • pembrolizumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma. / Simeone, Ester; Grimaldi, Antonio Maria; Festino, Lucia; Giannarelli, Diana; Vanella, Vito; Palla, Marco; Curvietto, Marcello; Esposito, Assunta; Palmieri, Giuseppe; Mozzillo, Nicola; Ascierto, Paolo Antonio.

In: OncoImmunology, Vol. 6, No. 3, e1283462, 04.03.2017.

Research output: Contribution to journalArticle

Simeone, Ester ; Grimaldi, Antonio Maria ; Festino, Lucia ; Giannarelli, Diana ; Vanella, Vito ; Palla, Marco ; Curvietto, Marcello ; Esposito, Assunta ; Palmieri, Giuseppe ; Mozzillo, Nicola ; Ascierto, Paolo Antonio. / Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma. In: OncoImmunology. 2017 ; Vol. 6, No. 3.
@article{e6550749dfd547728dd26a37a914a77a,
title = "Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma",
abstract = "The optimal sequencing of targeted treatment and immunotherapy in the treatment of advanced melanoma is a key question and prospective studies to address this are ongoing. Previous observations suggest that treating first with targeted therapy may select for more aggressive disease, meaning that patients may not gain full benefit from subsequent immunotherapy. In a single-center retrospective analysis, we investigated whether response to pembrolizumab was affected by previous BRAF inhibitor therapy. A total of 42 patients with metastatic cutaneous or mucosal melanoma who had received previous treatment with ipilimumab were treated with pembrolizumab as part of the Italian expanded access program. Sixteen of these patients had BRAF-mutated melanoma and had also been previously treated with a BRAF inhibitor (vemurafenib or dabrafenib), while 26 had BRAF wild-type melanoma (no previous BRAF inhibitor). Patients with BRAF-mutant melanoma who were previously treated with BRAF inhibitors had a significantly lower median progression-free survival (3 [2.3–3.7] versus not reached [2–8+] mo; p = 0.001) and disease control rate (18.6{\%} versus 65.4{\%}; p = 0.005) than patients with BRAF wild-type, while there was also a trend toward a lower response rate (assessed using immune-related response criteria) although this was not significantly different between groups (12.5{\%} versus 36.4{\%}; p = 0.16). These data are consistent with previous reports that BRAF inhibitor therapy may affect subsequent response to immunotherapy.",
keywords = "Anti-PD-1 antibodies, BRAF inhibitors, immunotherapy, melanoma, pembrolizumab",
author = "Ester Simeone and Grimaldi, {Antonio Maria} and Lucia Festino and Diana Giannarelli and Vito Vanella and Marco Palla and Marcello Curvietto and Assunta Esposito and Giuseppe Palmieri and Nicola Mozzillo and Ascierto, {Paolo Antonio}",
year = "2017",
month = "3",
day = "4",
doi = "10.1080/2162402X.2017.1283462",
language = "English",
volume = "6",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Taylor and Francis Inc.",
number = "3",

}

TY - JOUR

T1 - Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma

AU - Simeone, Ester

AU - Grimaldi, Antonio Maria

AU - Festino, Lucia

AU - Giannarelli, Diana

AU - Vanella, Vito

AU - Palla, Marco

AU - Curvietto, Marcello

AU - Esposito, Assunta

AU - Palmieri, Giuseppe

AU - Mozzillo, Nicola

AU - Ascierto, Paolo Antonio

PY - 2017/3/4

Y1 - 2017/3/4

N2 - The optimal sequencing of targeted treatment and immunotherapy in the treatment of advanced melanoma is a key question and prospective studies to address this are ongoing. Previous observations suggest that treating first with targeted therapy may select for more aggressive disease, meaning that patients may not gain full benefit from subsequent immunotherapy. In a single-center retrospective analysis, we investigated whether response to pembrolizumab was affected by previous BRAF inhibitor therapy. A total of 42 patients with metastatic cutaneous or mucosal melanoma who had received previous treatment with ipilimumab were treated with pembrolizumab as part of the Italian expanded access program. Sixteen of these patients had BRAF-mutated melanoma and had also been previously treated with a BRAF inhibitor (vemurafenib or dabrafenib), while 26 had BRAF wild-type melanoma (no previous BRAF inhibitor). Patients with BRAF-mutant melanoma who were previously treated with BRAF inhibitors had a significantly lower median progression-free survival (3 [2.3–3.7] versus not reached [2–8+] mo; p = 0.001) and disease control rate (18.6% versus 65.4%; p = 0.005) than patients with BRAF wild-type, while there was also a trend toward a lower response rate (assessed using immune-related response criteria) although this was not significantly different between groups (12.5% versus 36.4%; p = 0.16). These data are consistent with previous reports that BRAF inhibitor therapy may affect subsequent response to immunotherapy.

AB - The optimal sequencing of targeted treatment and immunotherapy in the treatment of advanced melanoma is a key question and prospective studies to address this are ongoing. Previous observations suggest that treating first with targeted therapy may select for more aggressive disease, meaning that patients may not gain full benefit from subsequent immunotherapy. In a single-center retrospective analysis, we investigated whether response to pembrolizumab was affected by previous BRAF inhibitor therapy. A total of 42 patients with metastatic cutaneous or mucosal melanoma who had received previous treatment with ipilimumab were treated with pembrolizumab as part of the Italian expanded access program. Sixteen of these patients had BRAF-mutated melanoma and had also been previously treated with a BRAF inhibitor (vemurafenib or dabrafenib), while 26 had BRAF wild-type melanoma (no previous BRAF inhibitor). Patients with BRAF-mutant melanoma who were previously treated with BRAF inhibitors had a significantly lower median progression-free survival (3 [2.3–3.7] versus not reached [2–8+] mo; p = 0.001) and disease control rate (18.6% versus 65.4%; p = 0.005) than patients with BRAF wild-type, while there was also a trend toward a lower response rate (assessed using immune-related response criteria) although this was not significantly different between groups (12.5% versus 36.4%; p = 0.16). These data are consistent with previous reports that BRAF inhibitor therapy may affect subsequent response to immunotherapy.

KW - Anti-PD-1 antibodies

KW - BRAF inhibitors

KW - immunotherapy

KW - melanoma

KW - pembrolizumab

UR - http://www.scopus.com/inward/record.url?scp=85014465478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014465478&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2017.1283462

DO - 10.1080/2162402X.2017.1283462

M3 - Article

AN - SCOPUS:85014465478

VL - 6

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 3

M1 - e1283462

ER -